Day: March 26, 2024

Microchip Technology Expands TrustFLEX Family with CEC1736 Real-time Platform Root of Trust Devices

Written by Customer Service on March 26, 2024. Posted in Public Companies.

TrustFLEX devices along with the Trust Platform Design Suite tool will simplify the enablement of root of trust from concept to production in wide range of applications CHANDLER, Ariz., March 26, 2024 (GLOBE NEWSWIRE) — As technology and cybersecurity standards continue to evolve, Microchip Technology (Nasdaq: MCHP) is helping make embedded security solutions more accessible with its CEC1736 TrustFLEX devices. The CEC1736 Trust Shield family is a microcontroller-based platform root of trust solution enabling cyber resiliency for data centers, telecom, networking, embedded computing and industrial applications. Now, as part of the TrustFLEX platform, the devices are partially configured and provisioned with Microchip-signed Soteria-G3 firmware to reduce the development time needed to integrate platform root of trust. These devices...

Gabelli Global Utility & Income Trust Appoints Nicolas W. Platt to Board of Trustees

Written by Customer Service on March 26, 2024. Posted in Public Companies.

RYE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) — The Board of Trustees of The Gabelli Global Utility & Income Trust (the “Board”) (NYSE American: GLU) (the “Fund”) announced the appointment of Nicolas W. Platt to the Board of the Fund effective February 13, 2024. Mr. Platt is a private investor and is a member of the NYSE American LLC Committee on Securities. In 2018, New Jersey Governor Phil Murphy appointed Mr. Platt to be one of two bipartisan “Czars” to address the State’s property tax crisis. He served as Mayor of the Township of Harding, New Jersey from 2013 to 2016, and currently serves on the Township Committee. From 2009 until 2011, Mr. Platt served as Managing Director of FTI Consulting Inc., an international financial consulting company. Prior to March 2009, he was a senior executive with WPP Group, plc subsidiaries...

GDS Appoints Jamie Khoo As CEO of GDS International

Written by Customer Service on March 26, 2024. Posted in Public Companies.

SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS”, “GDSH” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced the appointment of Ms. Jamie Khoo, currently the Chief Operating Officer (“COO”) of GDS, as the Chief Executive Officer (“CEO”) of DigitalLand Holdings Limited (“GDS International” or “GDSI”), the holding company for GDS’s international data center assets and operations. The appointment is effective at the closing of the Series A capital raise of GDS International which has been announced today. Concurrently, Jamie will step down as the COO of GDS. Her responsibilities as the COO of GDS will be assigned to Mr. Kejing Zhang, SVP, Sales, Ms. Yan Liang, SVP, Operational Excellence,...

GDS Announces Landmark US$587 Million Equity Raise For its International Business

Written by Customer Service on March 26, 2024. Posted in Public Companies.

SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) — GDS Holdings Limited (the “Company” or “GDSH”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced that GDSH’s wholly-owned subsidiary, DigitalLand Holdings Limited (“GDS International” or “GDSI”), that acts as the holding company for GDSH’s international data center assets and operations, has entered into definitive agreements for certain institutional private equity investors (the “Investors”) to subscribe for US$587 million of Series A convertible preferred shares (the “Series A”) newly issued by GDSI. This transaction is a significant step forward in the Company’s strategy to obtain dedicated financing for the development of its international business on a standalone basis. GDS International...

GDS Holdings Limited Reports Fourth Quarter and Full Year 2023 Results

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

SHANGHAI, China, March 26, 2024 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial HighlightsNet revenue increased by 6.3% year-over-year (“Y-o-Y”) to RMB2,556.5 million (US$360.1 million) in the fourth quarter of 2023 (4Q2022: RMB2,404.0 million). Net loss was RMB3,164.6 million (US$445.7 million) in the fourth quarter of 2023 (4Q2022: net loss of RMB177.9 million). Adjusted EBITDA (non-GAAP) increased by 5.7% Y-o-Y to RMB1,132.6 million (US$159.5 million) in the fourth quarter of 2023 (4Q2022: RMB1,071.5 million). See “Non-GAAP Disclosure”...

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in H1 2024. $21.6 million in cash and cash equivalents as of December 31, 2023 Private placement financing in March 2024 raised upfront gross proceeds of approximately $16 million DOYLESTOWN, Pa., March 26, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “Aprea...

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

– Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 –– On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 – – 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 –– Webcast Conference Call Scheduled Today at 8:00 a.m. ET – PURCHASE, N.Y., March 26, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Management will host a live webcast conference call at 8:00am ET to review 2023 accomplishments. Details of the call are provided below. A number...

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less frequent dosing schedule to be explored in a cohort of ARTISTRY-6, the company’s ongoing phase 2 trial in patients with melanoma Mural Oncology intends to nominate development candidates for its engineered therapies targeting interleukin-18 and interleukin-12 in 2024 The company reiterates cash runway projection into 4Q 2025 WALTHAM, Mass. and DUBLIN, Ireland, March 26, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address...

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Written by Customer Service on March 26, 2024. Posted in Earnings Releases And Operating Results.

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease expected in the first half of 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $306.1 million as of Dec. 31, 2023, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ETCHARLOTTESVILLE, Va., March 26, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported...

Purpose Investments Inc. Announces Final March 2024 Distribution Rate for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund

Written by Customer Service on March 26, 2024. Posted in Dividend Reports And Estimates.

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) — Purpose Investments Inc. announced today the final March 2024 distribution rates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund. The following table reflects the final distribution amounts for the month of March. Ex-distribution date is March 27, 2024.Open-End Fund Ticker Symbol Final distribution per unit Record Date Payable Date Distribution FrequencyPurpose USD Cash Management Fund – ETF Units MNU.U US $ 0.4197 03/27/2024 04/05/2024 MonthlyPurpose Cash Management Fund – ETF Units MNY $0.3879 03/27/2024 04/05/2024 MonthlyPurpose High Interest Savings Fund – ETF Units PSA $0.1876 03/27/2024 04/05/2024 MonthlyPurpose US Cash Fund – ETF Units PSU.U US $ 0.3966 03/27/2024 04/05/2024 MonthlyAbout...

Day: March 26, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice